192 related articles for article (PubMed ID: 35810370)
1. The safety and persistence of intravenous iloprost in systemic sclerosis.
Martins P; Dourado E; Fonseca JE; Romão V; Resende C
ARP Rheumatol; 2022; 1(2):122-128. PubMed ID: 35810370
[TBL] [Abstract][Full Text] [Related]
2. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
[TBL] [Abstract][Full Text] [Related]
3. The safety of iloprost in systemic sclerosis in a real-life experience.
Bellando-Randone S; Bruni C; Lepri G; Fiori G; Bartoli F; Conforti ML; Moggi-Pignone A; Guiducci S; Giuggioli D; Colaci M; Spinella A; Ferri C; Matucci-Cerinic M
Clin Rheumatol; 2018 May; 37(5):1249-1255. PubMed ID: 29470737
[TBL] [Abstract][Full Text] [Related]
4. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study.
Negrini S; Magnani O; Matucci-Cerinic M; Carignola R; Data V; Montabone E; Santaniello A; Adorni G; Murdaca G; Puppo F; Indiveri F; Della Rossa A; D'Ascanio A; Barsotti S; Giuggioli D; Ferri C; Lumetti F; Bosello SL; Canestrari G; Bellando Randone S; Bruni C; Guiducci S; Battaglia E; De Andres MI; Russo AA; Beretta L
Clin Exp Med; 2019 Aug; 19(3):357-366. PubMed ID: 30989453
[TBL] [Abstract][Full Text] [Related]
5. Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic.
De Lorenzis E; Natalello G; Verardi L; Cerasuolo PG; Gigante L; D'Agostino MA; Bosello SL
Microvasc Res; 2022 Nov; 144():104404. PubMed ID: 35835174
[TBL] [Abstract][Full Text] [Related]
6. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study.
Colaci M; Lumetti F; Giuggioli D; Guiducci S; Bellando-Randone S; Fiori G; Matucci-Cerinic M; Ferri C
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):179-183. PubMed ID: 28980901
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
10. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
[TBL] [Abstract][Full Text] [Related]
12. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
[TBL] [Abstract][Full Text] [Related]
14. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Janssena MC; Wollersheim H; Kraus C; Hildebrand M; Watson HR; Thien T
Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645
[TBL] [Abstract][Full Text] [Related]
18. Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review.
Jamart C; Levesque H; Thietart S; Fain O; Rivière S; Benhamou Y; Mekinian A
Front Med (Lausanne); 2022; 9():878970. PubMed ID: 35872796
[TBL] [Abstract][Full Text] [Related]
19. Digital ulcers in scleroderma patients: A retrospective observational study.
De Cata A; Inglese M; Molinaro F; De Cosmo S; Rubino R; Bernal M; Mazzoccoli G
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):180-7. PubMed ID: 26684622
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis.
Di Battista M; Della Rossa A; Da Rio M; De Mattia G; Morganti R; Mosca M
J Rheumatol; 2023 Aug; 50(8):1029-1031. PubMed ID: 37003608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
